Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$26.65 +1.9%	$19.60	$7.75 ▼ $26.77	$200.63M	0.64	114,365 shs	186,859 shs
CPIX Cumberland Pharmaceuticals	$3.24 -0.3%	$3.51	$1.04 ▼ $7.25	$48.62M	-0.39	77,507 shs	17,914 shs
NKTR Nektar Therapeutics	$28.00 +3.9%	$22.50	$6.45 ▼ $37.38	$512.55M	0.95	659,475 shs	816,077 shs
OMER Omeros	$4.48 +6.9%	$3.64	$2.95 ▼ $13.60	$285.15M	2.26	1.66 million shs	1.40 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	+1.91%	+6.77%	+42.67%	+97.12%	+78.86%
CPIX Cumberland Pharmaceuticals	-0.31%	+8.36%	-4.71%	-36.22%	+133.09%
NKTR Nektar Therapeutics	+3.90%	+4.91%	+14.38%	+185.38%	+46.98%
OMER Omeros	+6.92%	+8.74%	+19.79%	+41.77%	+5.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASMB Assembly Biosciences	4.1642 of 5 stars	3.4	4.0	4.7	4.0	0.0	0.0
CPIX Cumberland Pharmaceuticals	0.5422 of 5 stars	0.0	3.0	0.0	1.9	1.7	0.0
NKTR Nektar Therapeutics	4.339 of 5 stars	3.4	4.0	4.2	3.1	2.5	0.0
OMER Omeros	4.1511 of 5 stars	3.4	2.0	4.4	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.75	Moderate Buy	$38.67	45.09% Upside
CPIX Cumberland Pharmaceuticals	0.00	N/A	N/A	N/A
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	215.48% Upside
OMER Omeros	2.83	Moderate Buy	$18.00	301.79% Upside

Current Analyst Ratings Breakdown

Latest ASMB, NKTR, OMER, and CPIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	ASMB Assembly Biosciences	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/18/2025	ASMB Assembly Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
8/15/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/15/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
7/25/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
6/30/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
6/27/2025	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00
6/10/2025	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$28.52M	7.17	N/A	N/A	$2.36 per share	11.29
CPIX Cumberland Pharmaceuticals	$37.87M	1.28	$0.26 per share	12.64	$1.85 per share	1.75
NKTR Nektar Therapeutics	$98.43M	5.41	N/A	N/A	($1.27) per share	-22.05
OMER Omeros	N/A	N/A	N/A	N/A	($3.36) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$40.18M	-$5.58	N/A	N/A	N/A	-117.20%	-149.01%	-39.04%	11/6/2025 (Estimated)
CPIX Cumberland Pharmaceuticals	-$6.48M	-$0.22	N/A	∞	N/A	-6.97%	7.48%	2.66%	11/4/2025 (Estimated)
NKTR Nektar Therapeutics	-$118.96M	-$8.80	N/A	N/A	N/A	-163.17%	-631.43%	-58.21%	11/6/2025 (Estimated)
OMER Omeros	-$156.82M	-$2.11	N/A	N/A	N/A	N/A	N/A	-55.49%	N/A

Latest ASMB, NKTR, OMER, and CPIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	OMER Omeros	-$0.55	-$0.53	+$0.02	-$0.43	$0.31 million	$28.60 million
8/7/2025	Q2 2025	NKTR Nektar Therapeutics	-$3.13	-$2.95	+$0.18	-$2.95	$9.42 million	$11.18 million
8/6/2025	Q2 2025	ASMB Assembly Biosciences	-$1.73	-$1.33	+$0.40	-$1.33	$5.30 million	$9.63 million
8/5/2025	Q2 2025	CPIX Cumberland Pharmaceuticals	N/A	$0.02	N/A	-$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	1.64	1.64
CPIX Cumberland Pharmaceuticals	0.19	1.30	1.17
NKTR Nektar Therapeutics	N/A	2.61	2.61
OMER Omeros	N/A	0.81	1.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
CPIX Cumberland Pharmaceuticals	15.51%
NKTR Nektar Therapeutics	75.88%
OMER Omeros	48.79%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	5.30%
CPIX Cumberland Pharmaceuticals	44.85%
NKTR Nektar Therapeutics	5.25%
OMER Omeros	12.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	100	7.67 million	7.27 million	Optionable
CPIX Cumberland Pharmaceuticals	80	14.96 million	8.25 million	Optionable
NKTR Nektar Therapeutics	220	19.02 million	18.02 million	Optionable
OMER Omeros	210	68.06 million	59.28 million	Optionable

ASMB, NKTR, OMER, and CPIX Headlines

Recent News About These Companies

Cantor Fitzgerald Lifts Earnings Estimates for Omeros

August 21 at 2:23 AM | americanbankingnews.com

Omeros: Deja Vu All Over Again (Rating Downgrade)

August 20 at 5:10 AM | seekingalpha.com

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

August 19 at 5:07 PM | seekingalpha.com

Omeros Corporation (NASDAQ:OMER) Q2 2025 Earnings Call Transcript

August 19 at 9:30 AM | insidermonkey.com

Omeros' (OMER) Buy Rating Reaffirmed at D. Boral Capital

August 18, 2025 | americanbankingnews.com

Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER)

August 18, 2025 | americanbankingnews.com

D. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER)

August 17, 2025 | marketbeat.com

Omeros (NASDAQ:OMER) Given "Hold" Rating at Needham & Company LLC

August 17, 2025 | marketbeat.com

Omeros (NASDAQ:OMER) Announces Earnings Results, Misses Estimates By $0.07 EPS

August 16, 2025 | marketbeat.com

Omeros Shares Gain on Narrower 2Q Loss

August 15, 2025 | marketwatch.com

FDA delays Omeros' 2nd attempt at transplant drug's approval by 3 months

August 15, 2025 | fiercebiotech.comF

Omeros Corporation Reports Q2 2025 Financial Results

August 15, 2025 | msn.com

Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ...

August 15, 2025 | gurufocus.com

Q2 2025 Omeros Corp Earnings Call Transcript

August 14, 2025 | gurufocus.com

Omeros reports Q2 EPS (44c), consensus (55c)

August 14, 2025 | msn.com

Omeros: Q2 Earnings Snapshot

August 14, 2025 | sfgate.com

Omeros Corporation Reports Second Quarter 2025 Financial Results

August 14, 2025 | businesswire.com

Retail investors who hold 55% of Omeros Corporation (NASDAQ:OMER) gained 12%, institutions profited as well

August 12, 2025 | finance.yahoo.com

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

August 11, 2025 | businesswire.com

Critical Comparison: Demant A/S (OTCMKTS:WILYY) & Omeros (NASDAQ:OMER)

August 11, 2025 | americanbankingnews.com

Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ASMB, NKTR, OMER, and CPIX Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$26.65 +0.50 (+1.91%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$26.70 +0.05 (+0.17%)

As of 08/21/2025 06:22 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.24 -0.01 (-0.31%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$3.26 +0.02 (+0.77%)

As of 08/21/2025 04:10 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Nektar Therapeutics NASDAQ:NKTR

$28.00 +1.05 (+3.90%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$27.69 -0.31 (-1.11%)

As of 08/21/2025 07:50 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Omeros NASDAQ:OMER

$4.48 +0.29 (+6.92%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$4.49 +0.01 (+0.22%)

As of 08/21/2025 07:48 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time